1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Breast Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

DelveInsight’s, “ Breast Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
- A snapshot of the global Market therapeutics scenario for Breast Cancer.
- A review of the marketed products under prescription for Breast Cancer, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Breast Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Breast Cancer drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Breast Cancer drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Breast Cancer drugs.
- Coverage of Breast Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Breast Cancer key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Breast Cancer.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to ‘Disease’.
- API intelligence over marketed drugs for Breast Cancer and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Breast Cancer.
- Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Breast Cancer- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Route of Synthesis
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Phase III Drugs Information
- Phase III Drugs Description
- The United States Drug Master Filings (US DMF)
- Discontinued Drugs Information

List of Tables
Breast Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Breast Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Breast Cancer Therapeutic Market, US, (Year), 2014
Breast Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2014
Breast Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Breast Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Breast Cancer Therapeutic Market, Global Sales (in million USD), 2014
Breast Cancer Marketed Drugs, API Manufacturers, Global, 2014
Breast Cancer Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Breast Cancer, 2014

List of Figures
Breast Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Breast Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Breast Cancer Therapeutic Market, US, (Year), 2014
Breast Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Breast Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Breast Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Breast Cancer Therapeutic Market, Global Sales (in million USD), 2014
Breast Cancer Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and ...

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

“Blood Tests replace Surgical Biopsies. Single screening test for all cancers announced .....” The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics ...


Download Unlimited Documents from Trusted Public Sources

Lymphoma Statistics in Germany

  • March 2017
    167 pages
  • Lymphoma  

    Cancer  

    Leukemia  

  • Germany  

    Europe  

    United States  

View report >

Hospital Statistics in the US

  • March 2017
    16 pages
  • Hospital  

    Breast Cancer  

  • United States  

View report >

Cancer Statistics in the Netherlands

  • March 2017
    21 pages
  • Cancer  

  • Netherlands  

View report >

Cancer Statistics

22 days ago

Related Market Segments :

Breast Cancer

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.